

UNIMORE

Maria Paola COSTI <costimp@unimore.it>

Hi Maria Paola, Don't Miss Out: Exciting Upcoming Events in Our OHD Newsletter

1 messaggio

OneHealthDrugs COST Action <onehealthdrugs.events@gmail.com>

29 aprile 2024 alle ore 09:15

Rispondi a: onehealthdrugs.events@gmail.com

A: mariapaola.costi@unimore.it

If you can't see this newsletter properly, please click [here](#)[Action Site](#) [COST Action](#) [LinkedIn](#) [YouTube](#) [X-Twitter](#)**In this edition ...**

- Don't Miss Out: **Exciting Upcoming Events**
- **Publication in the ACS Infectious diseases Issue** deadline 31st of May
- **OHD May & June Upcoming events**

- OHD Action **project related meetings**
- Launching the Stakeholder Engagement Program: **Inaugural Discussion with SYNet of the PARC.EU Project**
- **OHD available positions**

Message from the Action Chair

by [Maria-Paola Costi](#), Action Chair

Dear Valued OneHealthDrugs Members,

I am delighted to share some uplifting news in our continuous journey toward scientific advancement and community growth.

Firstly, our engagement with the ACS Infectious Diseases Issue has been phenomenal. We are currently **on track with about 35 articles** submitted for the upcoming issue, all set for the submission deadline on 1st May. This represents a significant contribution from our community, underscoring our commitment to **advancing research in infectious diseases**. Your diligent efforts and high-quality work are greatly appreciated and are sure to make a substantial impact within the scientific community.

Additionally, **I am thrilled to announce that our grants from the COST Action have increased by 15%**. This increase is a testament to the hard work and success of our members in securing funding and advancing our collective research objectives. It also **reflects the growing recognition** and support for the valuable work we are doing here at OHD.

These developments not only bolster our resources but also enhance our ability to conduct cutting-edge research and foster collaborations that drive innovation in our field. Let us continue to push the boundaries of what we can achieve together.

We plan to allocate most of this additional funding to support greater participation at the upcoming **Oxford conference** from 3-5 July. Furthermore, we might increase the funding for the **Athens conference** in September if there are any funds remaining.

We have also managed to support more **Young Researchers and Innovators (YRI)** at the Rome conference by reallocating some unused STSM grant funds. Additionally, we are reviewing the participant list for the **Porto meeting** to see if more places can be made available.

The **Training school in Naples**, focusing on Natural Products, has garnered exceptional interest, particularly from our YRI. We are considering increasing the

number of participants should there be more requests.

Your feedback has been instrumental in enabling us to increase participant numbers for our in-person meetings. Please continue to plan ahead and adhere to the administrative office's guidelines to ensure effective use of funds and maximize scientific participation.

You may also have noticed the breadth of our dissemination efforts. We are committed to extensive dissemination activities to ensure our research reaches as wide an audience as possible.

Thank you for your exceptional contributions and for making these successes possible!



Announcement: Upcoming Deadline for ACS Infectious Diseases Issue Submission

Attention OHD members: The submission deadline for the upcoming ACS Infectious Diseases Issue is rapidly approaching on 1st May. We currently have around 35 articles slated for inclusion in this special issue, showcasing the extensive research and expertise within our community. Please ensure your manuscripts are ready and submitted by the deadline to be part of this significant publication.



Let's make a substantial impact together in the field of infectious diseases! I wish to submit a publication!

OHD May & June Upcoming events


OneHealthDrugs fans and followers, join us to shape the future of health innovations. You're invited to a series of transformative events where science meets sustainability.



This year, our focus is on revolutionizing healthcare through groundbreaking research and collaborative innovation. Secure your place today and be part of our upcoming events. Your insights are vital in driving the next wave of health solutions.

* Rome meeting for YRI (contact Elisa Uliassi) 14 grant participation for YRI supported

Environmentally Friendly Systems to Replace Classical Animal Models in Drug Testing for VBD



Kick things off in May at the beautiful **Porto, Portugal**. Dive into our workshop on 'Environmentally Friendly Systems to Replace Classical Animal Models in Drug Testing for VBD'. Join us from **May 14th to the 15th** and participate in our 'Young

Innovators Mini-Workshop', where future science leaders blossom.

[Learn more here](#)

* Porto meeting contact: Contact Ioana Tavares and Ana Tomas - Free registration for the Hybrid event

Natural Products Training School



Natural Products Training School
Natural products in antiparasitic drug discovery:
experimental and computational approaches

Tuesday 18 June – Thursday 20 June 2024
Department of Pharmacy-University of Naples


The banner features a central circular graphic with a mouse and a plant, surrounded by icons of a globe, a chemical structure, a microscope, and a computer monitor. Text on the left side of the circle reads: 'in animal models in drug testing for VDR'.

Fast forward to June for our '**Natural Products Training School**' at the **University of Naples**, exploring the rich potential of natural sources in antiparasitic drug discovery. Engage hands-on from the **18th to the 20th of June**.

[Learn more here](#)

* Naples school on Natural products and antiparasitic drugs about 10-12 participation for YRI supported

Paul Ehrlich & OneHealthdrugs Meeting for YRIs



Continue the momentum in **Rome** at the '**Paul Ehrlich & OneHealthdrugs Meeting for Young Researchers and Innovators**', a critical convergence of ideas and strategies to tackle neglected infectious diseases on **June 17th to 19th**.

[Learn more here](#)

OneHealthDrugs Annual Conference



Cap off your summer at the prestigious '**OneHealthDrugs Annual Conference**' from

July 3rd to 5th in Oxford. Expect compelling discussions on drug discovery and the One Health approach, linking human, animal, and environmental health.

[Learn more here](#)

* Oxford annual meeting (contact Marco Mazzorana and MP Costi) about 40 grant participation supported

OHD Action project related meetings

Update on the OHD1_Target Database Initiative (Project OHD1 -Target Database 4-3-2024) Cecilia Pozzi and Ulrike Wittig and Marco Mazzorana

Highlights from the OHD1_Target database project (Project OHD1 -Target Database 4-3-2024)

The OHD1_Target database is progressing well, aligning with the objectives for WG1 – YEAR 2: to define the biological target criteria and commence the collection of target data. This ongoing effort also contributes to the deliverable:

D7_Report on target selection and structural biology. M36 (WG1)

This initiative is linked to the events scheduled for the 17th of April, titled "Structural and functional aspects of targets involved in vector borne diseases."

On March 4th at 15:38, we had a productive meeting where we introduced the project and began creating a template to gather information on the targets within the CA21111. We've started drafting a document to compile this data and have outlined the main sections and some parameters.

We've shared a folder for the BioTarget Database which can be accessed here:

[BioTarget Database Folder](#). Within this folder, you'll find the "BioTarget DB template CA21111.docx" file here: [BioTarget DB Template](#).

Please feel free to add new sections or parameters, and suggest any modifications to the existing content.

OUTCOME: Target collection for VBPD, new potential targets to be identified, new profile expected for these targets including the predictive distribution among organisms present in the environment.

Highlights from the OHD2_Compounds database project

(Project OHD2- Compounds Database 11-3-2024)

This project is designed with dual objectives: to develop both a database and a scholarly article. The anticipated research paper, titled "Antiparasitic Drug Discovery and Emerging Scaffold with Predictive Low Environmental Impact," aligns with our Year 2 goal to "Upload of compound data and set up database structure [WG1 + WG2]." This initiative also ties into the in silico assessment of ecotoxicology properties of hits and leads [WG2 + WG3 + HG6 + HG7], as it includes an ecotoxicological evaluation of the scaffolds. Additionally, this effort contributes to deliverable D18_Report about compound collections, due in Month 48 (WG1).

Outcome: The research paper is structured, and the compilation of compound data over the past five years has commenced. The selection criteria for these compounds are based on scaffold collections, which are pertinent to the target product profile for hit compounds across various diseases. These scaffolds are also being analyzed for their predictive ecotoxicology profiles, ensuring a comprehensive assessment of their environmental impact.

OHD3 Animal models in VBPD. Paper SOP animal models -20-3-11.30am meeting

This activity aligns with the Year 1 objectives of WG3, specifically focusing on the "SOP Coordination for Animal Experiment Standardization" and the development of a "Roadmap toward a Position Paper on Animal Experiment Standardization." It also contributes to the deliverable D14_Report on SOP Coordination on Standardization of Animal Experiments, scheduled for Month 42 (WG3).

Abstract

Background: The development of treatments for neglected tropical diseases caused by kinetoplastids, such as *Leishmania*, *Trypanosoma brucei* spp., and *Trypanosoma cruzi*, faces significant challenges. These include not only limited funding but also the variability in experimental methods used across different laboratories. This diversity in methodologies complicates the comparison of research results and influences decision-making in the drug development pipeline.


Objectives: This review seeks to summarize and compare all existing research methodologies employed in the development of treatments for visceral and cutaneous leishmaniasis, African trypanosomiasis, and Chagas disease. It aims to develop a series of well-considered standard operating procedures (SOPs) that will standardize and streamline future drug development efforts.

Conclusions: The review provides a comprehensive list of standard operating procedures, particularly focusing on in vivo animal models, and offers a valuable tool for decision-making in transitioning from in vitro to in vivo research. This will support the

development of high-quality drug leads by ensuring consistency and reliability in experimental approaches.

Outcome: The result of this activity is the standardization of SOPs and enhanced communication among stakeholders, facilitating more uniform practices across the field.

Launching the Stakeholder Engagement Program: Inaugural Discussion with SYNnet of the **PARC.EU** Project



Stakeholder engagement

PARC SYNnet - One Health Drugs and PARC meeting to promote the establishment of synergies

We are starting our interaction with the PARC-EU project within the SYNnet area (please, see below). There was a first meeting on 5 April.

The PARC colleagues in CC are WP8 (Concepts and toolboxes) and WP9 (Building infrastructural and human capacities) co-leaders and [@Maria Paola COSTI](#) is One Health Drugs representative discuss bilaterally potential synergies.

What is **PARC.EU**?

PARC is a collaborative effort that brings together 200 partners from 29 European countries and aiming to develop next-generation chemical risk assessment to protect human health and the environment. Given its size and scope, PARC aims to play a leading role in European research projects focusing on chemical risk assessment.

Mission

PARC's mission is to address current, emerging and novel chemical safety challenges and enabling the transition to the Next Generation Risk Assessment (NGRA), in line with the European Green Deal's zero-pollution ambition for a toxic free environment and in particular with the Chemicals Strategy for Sustainability Towards a Toxic-Free Environment.

Objectives

The PARC programme has three main objectives:

Develop the scientific skills needed to address current and future challenges in chemical safety

Provide new data, methods and innovative tools to those responsible for assessing and managing the risks of chemical exposure

Strengthen the networks which bring together actors specialised in the different scientific fields contributing to risk assessment.

Synergy

OHD will collaborate with the SynNet program to leverage synergistic activities. We've identified promising contacts and opportunities to jointly develop concepts, author papers, and organize workshops.

P-A-R-C



Join the OneHealthdrugs LinkedIn Group!



Help us shape the OHD Network: Identify Key Stakeholders

This survey is designed to gather insights from OHD members on identifying key stakeholders for the One Health Drugs Dissemination & Exploitation. Your valuable input will help us understand our network better and facilitate more effective collaborations.

Start

OHD available positions



- WG6 Leadership
- WG4-Vice leader
- Young Researcher and Innovators

I wish to share with the OHD Community

Give us your valuable feedback

We will be pleased to answer any questions you may have or consider suggestions for improving our Community.

Please email us at onehealthdrugs.events@gmail.com

Contact us if you have any questions,
suggestions or you wish to share your news



CA21111 - One Health drugs against parasitic vector borne diseases in Europe and beyond (OneHealthdrugs)

[Unsubscribe me](#) | [Change my information](#)